Sandbox:Hannan1: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 410: Line 410:
|
|
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |Appendix neuroendocrine tumors<ref name="pmid28761642">{{cite journal |vauthors=Abdelaal A, El Ansari W, Al-Bozom I, Khawar M, Shahid F, Aleter A, Abunuwar MR, El-Menyar A |title=Frequency, characteristics and outcomes of appendicular neuroendocrine tumors: A cross-sectional study from an academic tertiary care hospital |journal=Ann Med Surg (Lond) |volume=21 |issue= |pages=20–24 |date=September 2017 |pmid=28761642 |doi=10.1016/j.amsu.2017.07.043 |url=}}</ref>
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |Appendix neuroendocrine tumors<ref name="pmid28761642">{{cite journal |vauthors=Abdelaal A, El Ansari W, Al-Bozom I, Khawar M, Shahid F, Aleter A, Abunuwar MR, El-Menyar A |title=Frequency, characteristics and outcomes of appendicular neuroendocrine tumors: A cross-sectional study from an academic tertiary care hospital |journal=Ann Med Surg (Lond) |volume=21 |issue= |pages=20–24 |date=September 2017 |pmid=28761642 |doi=10.1016/j.amsu.2017.07.043 |url=}}</ref><ref name="pmid23365545">{{cite journal |vauthors=Holt N, Grønbæk H |title=Goblet cell carcinoids of the appendix |journal=ScientificWorldJournal |volume=2013 |issue= |pages=543696 |date=2013 |pmid=23365545 |doi=10.1155/2013/543696 |url=}}</ref>
|
|
* Asymptomatic
* Asymptomatic

Revision as of 16:04, 29 January 2019

Neuroendocrine tumor Clinical manifestations Dianosis Gold

standard

Other features
Symptoms Signs Blood & Urine Gross Histology Immunohistochemistry Imaging Others
Medullary thyroid carcinoma[1][2][3]
  • Dysphagia
  • Hoarseness
  • Respiratory difficulty
  • Flushing
  • Diarrhea
  • Weight loss
  • Palpable neck mass
  • Signs of Cushing syndrome
  • ↑ Calcitonin
  • ↑ Serum calcium
  • ↑ or - Cortisol
  • ↑ CEA level
  • White or gray in color
  • Firm to palpation
  • Nests of uniform cells
  • Deposition of stromal amyloid
  • Granular chromatin
  • C-cell hyperplasia
  • Calcitonin
  • Chromogranin A
  • Carcinoembryonic antigen (CEA)
  • Solid thyroid nodule (US)
  • CT scan/MRI and PET scan for metastatis
  • Genetic testing
  • FNA cytology with immunohisto-

chemistry and

calcitonin levels

  • Associated with MEN 2A and 2B
  • Familial association with RET mutations
  • May present as Cushing syndrome
Pheochromocytoma[4][5][6][7][8]
  • Headaches
  • Palpitations
  • Excessive sweating
  • Anxiety
  • Pallor
  • Pain in chest/abdomen
  • Weakness, fatigue
  • Nausea/vomiting
  • Dizziness
  • Paresthesias
  • Constipation (rarely diarrhea)
  • Visual disturbance
  • Hypertension
  • Postural hypotension
  • Tachycardia or reflex bradycardia
  • Tremulousness
  • Pallor
  • Flushing (rare)
  • Weight loss
  • Fasting hyperglycaemia
  • Decreased GI motility
  • Pallor
  • ↑ Respiratory rate
  • Psychosis
  • ↑ Plasma and urine catecholamines
  • ↑ Plasma and urine metanephrines
  • ↑ Chromogranin A
  • ↑ Plasma methoxytyramine
  • N/A
  • Loosely cohesive clusters
  • Scattered tumor cells with prominent anisokaryosis, abundant eosinophilic granular cytoplasm and indistinct cell borders
  • Occasional binucleate cells
  • Chromogranin A (CGA)
  • Protein gene product (PGP) 9.5
  • Synaptophysin (SYN)
  • CD56 (also known as neural cell adhesion molecule or N-CAM)
  • Glial fibrillary acidic protein (GFAP)
  • Heterogeneous appearance, often with some cystic areas. Calcifications or hemorrhage may also be present (CT)
  • T2-bright lesions, with/without cystic or necrotic components (MRI)
  • Cystic or solid with necrotic areas or hemorrhages (U/S)
  • Genetic testing
  • Provacative glucagon test
  • Clonidine suppression test
  • Metaiodobenzyl-guanidine scintigraphy
  • PET scan
  • Octereoscan
  • Plasma and urine catecholamines & metanephrines combined with clinical findings
  • May mimic panic attack
  • May be associated with Von Hippel-Lindau disease, MEN type 2 and Neurofibromatosis type 1.
  • Arise from the chromaffin cells
Merkel cell carcinoma[9][10][11]
  • Asymptomatic red-to-violet nodules
  • Violaceous nodule
  • Ulcerated Nodule
  • Lympadenopathy
  • Seropositivity for Merkel cell polyomavirus
  • Anti-ST antibodies
  • Dermal and subcutaneous nodule
  • Monomorphic cells with 3 main types — small-cell, trabecular and intermediate
  • May show necrosis & pleomorphism
  • Epidermotropism
  • Chromogranin-A
  • Synaptophysin
  • Cytokeratin 20 (CK20)
  • Merkel cell polyomavirus (MCPyV) large T antigen
  • U/S, CT scan, MRI and PET scan for metastasis
  • N/A
  • Biopsy with immunohisto-chemistry
  • Higher mortality than melanoma
  • ↑ Risk in immun-compromised
Parathyroid adenoma[12][13][14]
  • Depression
  • Memory loss
  • Fatigue
  • Sleep problems
  • Bone or muscle pains
  • GERD
  • ↓ concentration
  • Renal colic
  • Constipation
  • Nephrolithiasis
  • Nephrocalcinosis
  • osteopenia
  • osteoporosis
  • ↑ Serum and urinary Calcium
  • ↑ or N/L PTH
  • Enlarged
  • smooth
  • Soft
  • Reddish brown in color
  • Discrete with thin fibrous capsule
  • May be multinodular and irregular
  • Proliferation of a single cell type with solid to pseudo-glandular, follicular, and acinar structure
  • Chromogranin
  • Parathyroid hormone
  • Enlarged gland on U/S and 99mTc-sestamibi scintigraphy
  • Single photon emission computed tomography
Staining for
  • bcl-1
  • Ki67
  • p27
  • parafibromin
  • Biopsy
  • Associated with MEN
  • Associated with HPRT
Paraganglioma[15][16][17][18]
  • Headaches
  • Palpitations
  • Tinnitus
  • Decreased hearing
  • Localized pain
  • GI & intracranial hemorrhage
  • Cardiomyopathy Generalized weakness
  • Pallor
  • Hypertension
  • Localized mass
  • Orthostasis
  • Incidentalomas
  • Cranial nerve palsies
  • ↑ Plasma and urine catecholamines
  • ↑ Plasma and urine metanephrines
  • ↑ Chromogranin A
  • ↑ Plasma methoxytyramine
  • Clear margins
  • Encapsulated
  • Honeycomb or nests patterns separated by broad bands of fibrous tissue
  • Prominent vascularization
  • Argyrophilic fibers
  • Chromogranin A
  • Synaptophysin
  • CD56
  • S-100
  • Cytokeratin
  • Mass with an un-enhanced density
  • Internal Hemorrhage
  • Cystic changes
  • Necrosis
  • Internal calcifications
  • Genetic testing
  • Provacative glucagon test
  • Clonidine suppression test
  • Metaiodobenzyl-guanidine scintigraphy
  • PET scan
  • Octereoscan
N/A
  • Paragangliomas are similar to pheochromo-cytomas but arise outside adrenal medulla
Pituitary gland tumors
Neuroendocrine tumors of the testicles[19][20][21]
  • Painless scrotal mass & swelling
  • Scrotal pain
  • Carcinoid syndrome
  • Firm painless or painful scrotal mass & swelling
  • Flushing
  • Hydrocele
  • ↑ Serum NSE
  • ↑ Serum vanillylmandelic acid
  • ↑ Serum serotonin and serotonin metabolites
  • Well-defined
  • Non-capsulated
  • Calcified cyst
  • Hemorrhage & necrosis
  • Presence of argentaffin and argyrophilic cells
  • Monomorphous polygonal cells
  • Eosinophilic cytoplasm
  • Finely dispersed chromatin
  • Cytokeratin
  • Chromogranin
  • Synaptophysin
  • Serotonin
  • NSE
  • Vimentin
  • Well-defined solid hypoechoic mass (U/S)
  • Dense punctate calcifications (U/S)
For metastasis and grading:
  • CT scan
  • Octreotide scintigraphy
  • Pan GI endoscopy
  • Scrotal U/S with immunohisto-chemistry
  • May be associated with testicular teratoma
  • Normal serum levels of testicular tumor markers
Neuroendocrine tumors of the ovaries[22][23][24]
  • Lower abdominal pain & swelling
  • Carcinoid syndrome
  • Abdominal and/or pelvic mass
  • Ascites
  • Flushing
  • ↑ Urinary 5-hydroxyindole-acetic acid
  • ↑ Chromogranin A
  • ↑ or - CA 125
  • Well-defined
  • Smooth
  • Solid with cystic areas
  • Insular pattern with nested areas
  • Cells in groups and trabeculae arrangement
  • Mild to moderate nuclear pleomorphism
  • CD 56
  • Synaptophysin
  • Chromogranin
  • Solid ovarian mass with significant enhancement (MRI)
  • Ovarian solid mass (U/S)

For metastasis and grading:

  • CT scan
  • Octreotide scintigraphy
  • Pan GI endoscopy
  • N/A
  • CDX2 may distinguish primary ovarian NET from metastatic NET from GI tract
Thymic neuroendocrine cancer[25][26][27][28]
  • Chest pain
  • Cough
  • Respiratory distress
  • Cushing’s syndrome
  • Carcinoid syndrome (rare)
  • ↓ Breath sounds
  • Flushing
  • Cushing’s syndrome
  • Hypercalcemia
  • Usually normal
  • May see
    • ↑ Serum calcium & ACTH
    • ↑ Serum serotonin and its metabolites
  • Solid mass
  • Hemorrhage & necrosis
  • Calcification
  • Gross invasion
  • Small cells with scant cytoplasm
  • Trabeculae
  • Solid nests
  • Vascular invasion
  • Fine granular or vesicular chromatin
  • Keratins (AE1/AE3, CAM5.2)
  • Synaptophysin
  • Chromogranin
  • NSE
  • CD 56
  • Mediastinal mass
  • Necrotic areas
  • Unclear margins
  • Adjacent compression

For metastasis and grading:

  • PET scan
  • Endoscopy
  • H & E morphology
  • May co-exist with thymoma
  • Associated with MEN-1
Jejuno-Ileal neuroendocrine tumors
Appendix neuroendocrine tumors[29][30]
  • Asymptomatic
  • Acute appendicitis
    • localized pain
    • shifting pain
    • nausea, vomiting, anorexia
    • rectal bleeding
  • Carcinoid syndrome
  • Asymptomatic
  • Acute appendicitis
    • localized or generalized abdominal tenderness
    • fever
    • abdominal distension
  • Carcinoid syndrome
  • Normal
  • ↑ WBCs (appendicitis)
  • ↑ Bilirubin (appendicitis)
  • ↑ Urinary 5-hydroxyindole-acetic acid
  • ↑ chromogranin A
  • Ill-defined
  • Firm
  • Nodular
  • Infiltrates muscularis propria & periappendiceal fat
  • Solid clusters resembling goblet cells or signet ring cells & eosinophilic cytoplasm
  • Scattered Paneth cells
  • Single cells
  • Synaptophysin
  • Chromogranin A
  • CK
  • CEA
  • CDX-2
  • CAM 5.2
  • Thickened appendix wall (U/S and CT)
  • Appendicitis (U/S and CT)
    • inflamed appendix
    • peri-appendicular fluid
  • Chromogranin A enzyme linked immunoassay
  • FDG-PET
  • 111In-labelled octreotide scintigraphy
  • Histopathology
  • N/A
Colon neuroendocrine tumors[31][32][33][34]
  • Abdominal pain
  • Diarrhea
  • Hematochezia
  • Nausea
  • Asymptomatic
  • Carcinoid syndrome
  • Abdominal tenderness
  • Weight loss
  • Anemia related
  • ↑ chromogranin A
  • ↑ Urinary 5-hydroxyindole-acetic acid (rare)
  • ↓ Hb
  • Flat or depressed lesion
  • Plaque or polypod
  • Islands, glandular or trabeculae
  • Granular cytoplasm
  • salt and pepper chromatin
  • Lymphovascular invasion
  • Synaptophysin
  • Chromogranin
  • Wall thickening
  • Lumen narrowing
  • Colonoscopy
  • Chromogranin A enzyme linked immunoassay
  • PET scan
  • SSTR (somatostatin receptors) scintigraphy
  • Biopsy and histopathology
  • Cecum is most common location
  • ↑ prevalence in IBD patient population
Rectum neuroendocrine tumors[35][31][36][37]
  • Asymptomatic
  • Rectal pain
  • Pruritus
  • Hematochezia
  • Constipation
  • Carcinoid syndrome (rare)
  • Abdominal tenderness
  • Weight loss
  • Carcinoid signs (rare)
  • ↑ chromogranin A
  • ↑ Urinary 5-hydroxyindole-acetic acid (rare)
  • ↓ Hb
  • Small and multiple
  • Nodules or polypoid
  • Islands, glandular or trabeculae
  • Granular cytoplasm
  • salt and pepper chromatin
  • Mucin secretion (rare)
  • Synaptophysin
  • Chromogranin
  • Neuron-specific enolase
  • CD56
  • Rectal mass or nodule
  • Ulcerative mass (high grade)
  • Hemorrhage
  • Liver mass (metastatic)
  • Colonoscopy
  • Chromogranin A enzyme linked immunoassay
  • PET scan
  • SSTR (somatostatin receptors) scintigraphy
  • Biopsy and histopathology
  • May exist with adenocarcinoma
  • Exhibits malignant potential
Gastric neuroendocrine tumors Type I GNET[38][39][40]
  • Dyspepsia
  • Abdominal discomfort and/or pain
  • Anemia related
  • Neurological symptoms
  • Weight loss
  • Pallor
  • Neurological signs
  • ↑ Gastrin level
  • ↑ chromogranin A
  • ↓ Hb
  • ↓ Serum iron
  • ↓ Serum B12 levels
  • Flattened gastric folds
  • Multiple polyps or nodules
  • Dense core granules
  • Glandular or trabecular
  • Salt and pepper chromatin
  • Keratins
  • Chromogranin
  • NSE
  • Synaptophysin
  • VMAT 2
  • Well demarcated hypoechoiec lesions
  • Mucosal / submucosal
  • Regular borders
  • Gastroscopy
  • pH on gastric aspirate
  • Axial CT
  • Somatostatin receptor imaging
  • N/A
  • Chronic atrophic gastritis → gastric achlorhydria and hypergastrinaemia → proliferation of ECL cells → type 1 G-NETs
Type II GNET[38][39][41]
  • Abdominal pain and/or discomfort
  • Severe watery diarrhea
  • GI bleed
  • Anemia related
  • GERD
  • Abdominal tenderness
  • Hypercalcemia
  • Anemia related
  • ↑ Gastrin or gastrin precursors
  • ↑ Serum calcium
  • ↑ Chromogranin A
  • N/A
  • Dense core granules
  • Glandular or trabecular
  • Salt and pepper chromatin
  • Keratins
  • Chromogranin
  • NSE
  • Synaptophysin
  • Hypertrophied gastric mucosal folds
  • Well demarcated hypoechoiec lesions
  • Secretin test
  • pH on gastric aspirate
  • 111Indium Octreotide scintigraphy
  • 68Gallium-DOTATOC/DOTATATE PET/CT
  • N/A
  • Caused by gastrinoma
  • Most patient have MEN-1 syndrome → evaluate
Type III GNET[42][43][44]
  • Dyspepsia
  • Abdominal discomfort and/or pain
  • May present with carciniod syndrome
  • Weight loss
  • Anaemia related
  • Flushing
  • ↓ Hb
  • ↑ Urinary 5-hydroxyindole-acetic acid (rare)
  • Large lesion with poor margins
  • Ulcerated appearance
  • High grade
  • Invasive
  • Dense core granules
  • Glandular or trabecular
  • Keratins
  • NSE
  • Synaptophysin
  • Absence of surface villiform architecture
  • Single large lesion
  • Ulcerated appearance
  • Gastroscopy
  • CT
  • 111Indium octreotide scintigraphy
  • Biopsy and histopathological studies
  • Early involvement of regional lymph nodes
  • May present with metastatic disease at diagnosed
Type IV GNET[45][46][32]
  • Dyspepsia
  • Abdominal discomfort and/or pain
  • Weight loss
  • Anaemia related
  • ↑ Gastrin or gastrin precursors
  • ↑ Serum calcium
  • Invasion of adjacent structures
  • Large solid lesion
  • Solid structure
  • Necrosis
  • Atypia
  • Invasive
  • Synaptophysin
  • NSE
  • PGP9.5 positive
  • N/A
  • Gastroscopy
  • CT
  • 111Indium octreotide scintigraphy
  • Biopsy and histopathological studies
Structural abnormality → no HCL secretion → achlorhydria →

hypergastrinemia → hyperplasia

Duodenal neuroendocrine tumors Gastrinoma[47][48][49][50]
  • Atypical PUD
  • Abdominal pain and/or cramps
  • Esophagitis
  • GERD
  • Upper GI blee
  • Secretory diarrhea
  • Abdominal tenderness
  • Hypercalcemia
  • ↑ Gastrin or gastrin precursors
  • ↑ Serum calcium
  • ↑ Chromogranin A
  • N/A
  • Trabeculae
  • Solid nests
  • Presence of argentaffin and argyrophilic cells
  • Chromogranin A
  • Neuron-specific enolase
  • Synaptophysin
  • Gastrin
  • Diffuse erosive esophagitis, gastric and duodenal ulcer (Endoscopic gastroduo-denoscopy)
  • Enhancing lobulated lesion (CT)
  • Gastrin levels
  • Pancreatic polypeptide levels
  • Insulin levels
  • Glucagon levels
  • VIP levels
  • PET with gallium 68–labeled octreotide
  • Provocative secretin test & biopsy
  • Associated with MEN-1
Somatostatinomas[51][52][53][54]
  • Abdominal pain
  • Jaundice
  • Gastrointestinal bleeding
  • Diarrhea
  • Weight loss
  • Hypoglycemia related
  • Jaundice
  • Diabetes mellitus
  • Gallstones
  • Hypochlorhydria
  • Hypoglycemia related
  • ↑ Somatostatin
  • Anemia
  • Hyper or hypoglycemia
  • N/A
  • Acinar structures
  • Trabeculae
  • Psammoma body
  • Abundant fine granular cytoplasm
  • Salt and pepper chromatin
  • Chromogranin A
  • Neuron-specific enolase
  • Synaptophysin
  • Leu-7
  • Isodense
  • Hypervascular lesion
  • Dual phase CT
  • MRI
  • Endoscopic ultrasonography
  • 68Ga-DOTATATE
  • Octreoscan
  • Gastrin levels
  • Pancreatic polypeptide levels
  • Insulin levels
  • Glucagon levels
  • N/A
  • Associated with NF-1
Gangliocytic paraganglionomas[55][56][57][58]
  • GI bleed
  • Abdominal pain
  • Anemia related
  • Carcinoid syndrome (rare)
  • Anemia related
  • May mimic other neuroendocrine tumors such as somatostatinoma
  • ↓ Hb
  • ↑ Chromogranin A
  • May have ↑ urinary 5-hydroxyindole-acetic acid or serum somatostatin
  • Solid tumor
  • Ulceration
  • Sessile or polypod
  • Covered by the smooth
  • Spindle cells, ganglion-like cells and epithelioid cells
  • Nests and trabeculae
  • Chromogranine
  • AE1–3
  • Cytokeratins
  • S100
  • Neuron-specific enolase
  • Synaptophysin
  • CD56
  • Ampullary smooth mass (CT scan and endoscopic ultrasonography)
  • Endoscopic ultrasonography-guided FNA
  • Serum serotonin assay
  • Biopsy with immunohisto-chemistry
  • Associated with NF-1
Nonfunctioning NET[59]
  • Asymptomatic
  • GI bleed
  • Abdominal pain
  • Anemia related
  • Anemia related
  • ↓ Hb
  • Solid tumor
  • Trabecular or microlobular structure
  • Mucosal-submucosal tumor
  • Chromogranin A
  • Synaptophysin
  • Hormones such as gastrin, somatostatin, serotonin
  • CT scan
  • Endoscopic ultrasonography
  • Endoscopic ultrasonography-guided FNA
  • Biopsy with immunohisto-chemistry
  • May produce hormones but do not secrete
neuroendocrine carcinomas[60][61][62][63]
  • Upper abdominal pain
  • Abdominal Discomfort
  • Obstruction
  • Gastrointestinal bleeding
  • Constitutional
  • Anemia related
  • ↑ Chromogranin A
  • Progastrin-releasing peptide (pro-GRP)
  • Cytokeratin fragments (CKfr, CK8, 18, 19)
  • Solid tumor
  • Ulceration
  • Poorly differentiated
  • Necrosis
  • Lymphovascular invasion
  • Marked pleomorphism
  • Chromogranin A
  • Neuron-specific enolase
  • Synaptophysin
  • Protein-gene-product 9.5 (PGP 9.5)
  • CD56 (N-CAM)
  • Polypoid intraluminal mass (CT scan)
  • MRI
  • FDG-PET
  • Somatostatin receptor imaging (SRI)
  • Biopsy with immunohisto-chemistry
  • Typically non-functioning
  • May exist with adenocarcinoma
Pancreatic neuroendocrine tumours Gastrinoma[47][48][49][50]
  • Atypical PUD
  • Abdominal pain and/or cramps
  • Esophagitis
  • GERD
  • Upper GI blee
  • Secretory diarrhea
  • Abdominal tenderness
  • Hypercalcemia
  • ↑ Gastrin or gastrin precursors
  • ↑ Serum calcium
  • ↑ Chromogranin A
  • N/A
  • Trabeculae
  • Solid nests
  • Presence of argentaffin and argyrophilic cells
  • Chromogranin A
  • Neuron-specific enolase
  • Synaptophysin
  • Pancreastatin
  • Gastrin
  • Diffuse erosive esophagitis, gastric and duodenal ulcer (Endoscopic gastroduo-denoscopy)
  • Enhancing lobulated lesion (CT)
  • Gastrin levels
  • Insulin levels
  • Glucagon levels
  • VIP levels
  • PET with gallium 68–labeled octreotide
  • Indium-labelled octreotide (111In-octreotide)
  • Provocative secretin test & biopsy
  • Associated with MEN-1
Insulinoma[64][65][66][67]
  • Visual disturbances
  • Weakness
  • Seizures
  • Palpitations
  • Sweating
  • Hyperphagia/obesity
  • Tachycardia
  • Altered mental state
  • Amnesia
  • Confusion
  • Coma
  • Tremors
  • ↓ Blood sugar level
  • ↑ or inappropriately normal insulin level
  • ↑ Plasma proinsulin
  • Firm
  • Well-circumscribed nodule
  • Encapsulated mass
  • Solid or gyriform patterns
  • May be associated with nesidioblastosis
  • Amyloid
  • Chromogranin A
  • Neuron-specific enolase
  • Synaptophysin
  • CD56
  • Insulin
  • Hypervascular lesion (CT)
  • Calcification (malignant)
  • Homogeneously hypoechoic (endoscopic U/S)
  • MRI
  • Transabdominal U/S
  • C peptidelevel
  • Urinary Sulfonylurea
  • Pancreatic angiography
  • Transhepatic portal venous sampling (THPVS)
  • Intraoperative U/S
  • Intra-arterial calcium stimulation (IAC)
  • Associated with MEN-1
Glucagonoma[68][69][70][71]
  • Rash
  • Weight loss
  • Anemia
  • Diarrhea
  • Abdominal pain
  • Nausea or anorexia
  • DVT or PE related
  • Neurological symptoms
  • Weakness or fatigue
  • Necrotizing migratory erythema
  • Glossitis
  • Stomatitis
  • Cheilitis
  • Anemia related
  • DVT or PE related
  • Onychodystrophy
  • Peripheral edema
  • Depression
  • ↑ Glucagon levels
  • Diabetes or impaired fasting glucose
  • Hypoaminoacidemia
  • ↓ Serum zinc
  • ↓ Hb
  • N/A
  • Dense core granules
  • Nests pattern
  • Salt and pepper chromatin
  • Amphophilic cytoplasm
  • PGP 9.5
  • CAM 5.2
  • anti-glucagon
  • Chromogranin A
  • Neuron-specific enolase
  • Synaptophysin
  • Helical multiphasic contrast-enhanced CT scan
  • MRI
  • Somatostatin receptor scintigraphy (SRS)
  • FPET imaging technique with DOTA peptides
  • Serum parathyroid hormone, gastrin, insulin, pancreatic polypeptide, serotonin, VIP, prolactin and ACTH levels
  • Skin biopsy
  • N/A
  • Associated with MEN-1
Somatostatinoma[51][52][53]
  • Abdominal pain
  • Jaundice
  • Gastrointestinal bleeding
  • Diarrhea
  • Weight loss
  • Hypoglycemia related
  • Jaundice
  • Diabetes mellitus
  • Gallstones
  • Hypochlorhydria
  • Hypoglycemia related
  • ↑ Somatostatin
  • Anemia
  • Hyper or hypoglycemia
  • N/A
  • Acinar structures
  • Trabeculae
  • Psammoma body
  • Abundant fine granular cytoplasm
  • Salt and pepper chromatin
  • Chromogranin A
  • Neuron-specific enolase
  • Synaptophysin
  • Leu-7
  • Isodense
  • Hypervascular lesion
  • Dual phase CT
  • MRI
  • Endoscopic ultrasonography
  • 68Ga-DOTATATE
  • Octreoscan
  • Gastrin levels
  • Pancreatic polypeptide levels
  • Insulin levels
  • Glucagon levels
  • N/A
  • Associated with MEN-1
VIPoma[72][73][74][75]
  • Secretory diarrhea with odorless and tea colored stools
  • Lethargy
  • Nausea & vomiting
  • Muscle weakness & cramps
  • Tetany
  • Dehydration
  • Flushing
  • Cardiac arrhythmias, myopathy, tetany and hypovolemic shock (crisis)
  • ↑ VIP levels
  • ↑ Serum pancreatic polypeptide level
  • Hypokalemia
  • Hypomagnesemia
  • Hypochlorhydria
  • Hyperglycemia
  • Hypercalcemia
  • Encapsulated
  • Necrosis
  • Nested cells
  • Trabeculae
  • Secretory granules
  • Granular cytoplasm
  • Chromogrannin A
  • VIP
  • Pancreatic polypeptide
  • Encapsulated and necrotic mass (CT scan & MRI)
  • Somatostatin receptor scintigraphy
  • Endoscopic U/S
  • FPET imaging with DOTA peptides
  • VIP radioimmunoassay
  • Celiac, superior mesentericand renal angiography
  • Levels of other PNETs
  • VIP radioimmunoassay with clinical manifestations
  • Associated with MEN-1
ACTHoma[76][77][78][79]
  • Weight gain
  • Acne
  • Ophthalmologic discomfort
  • Extremity weakness
  • Hypertension
  • Moon facies
  • Easy bruising
  • Buffalo-hump
  • Abdominal striae
  • ↑ Serum ACTH
  • ↑ Serum and urinary cortisol
  • Diabetes mellitus
  • Hypokalemic alkalosis
  • Firm
  • Well circumscribed
  • Encapsulated
  • Nested cells
  • Trabeculae
  • Secretory granules
  • Lymphovascular invasion
  • Synaptophysin
  • Chromogranin A
  • ACTH
  • Hypoechoic, homogenous, solid mass (endoscopic U/S)
  • Dexamethasone suppression test
  • Somatostatin receptor scintigraphy (SRS)
  • FPET imaging
  • N/A
  • Osteoporosis
  • Menstrual irregularities
Lung neuroendocrine tumors Typical carcinoid tumours[80][81][82][83]
  • Asymptomatic
  • Constitutional
  • Cough
  • Hemoptysis
  • Recurrent pneumonia
  • Seizures
  • ↓ Breath sounds
  • Fever
  • Weight loss
  • Carcinoid syndrome related
  • Cushing's syndrome related
  • ↑ Urinary 5-hydroxyindole-acetic acid
  • ↑ Chromogranin A
  • Central
  • Polypoid
  • Usually well defined
  • Smooth
  • No necrosis
  • Organized structure
  • <2 mitoses/2 mm2
  • No necroses
  • Nesting and/or trabecular pattern
  • Synaptophysin
  • Chromogranin A
  • CD56/NCAM
  • TTF1
  • Estrogen receptor
  • N/L
  • Coin lesion
  • Enlarged lymph nodes
  • Mass (rare)
  • Bronchoscopy (Gold standard for tumor visualization)
  • Endoscopic biopsy
  • N/A
  • 5‐year survival rate >90%
  • 12% metastasis at presentation
Atypical carcinoid tumours[80][81][82][83]
  • Asymptomatic
  • Constitutional
  • Cough
  • Hemoptysis
  • Recurrent pneumonia
  • Seizures
  • ↓ Breath sounds
  • Fever
  • Weight loss
  • Carcinoid syndrome related
  • Cushing's syndrome related
  • ↑ Urinary 5-hydroxyindole-acetic acid
  • ↑ Chromogranin A
  • Peripheral
  • Polypoid
  • Irregular margins
  • Smooth
  • Necrosis
  • More pleomorphism
  • 2–10 mitoses/2 mm2
  • Necroses
  • Nesting and/or trabecular pattern
  • Synaptophysin
  • Chromogranin A
  • CD56/NCAM
  • TTF1
  • Estrogen receptor
  • N/L
  • Coin lesion
  • Enlarged lymph nodes
  • Mass (rare)
  • Bronchoscopy (Gold standard for tumor visualization)
  • Endoscopic biopsy
  • N/A
  • 5‐year survival rate 40-75%
  • 50% metastasis at presentation
Large cell lung neuroendocrine carcinomas[84][85][86][87]
  • Asymptomatic
  • Cough
  • Hemoptysis
  • Recurrent infections
  • Seizures
  • ↓ Breath sounds
  • Fever
  • Carcinoid syndrome related (rare)
  • Cushing's syndrome related (rare)
  • ↑ Urinary 5-hydroxyindole-acetic acid (rare)
  • ↑ Serum ACTH (rare)
  • ↑ Chromogranin A
  • Less differentiated
  • Grey-white
  • Invasive
  • Hemorrhage/necrosis
  • Organoid or trabecular pattern
  • Rosette-like structures
  • Cells are ×3 the diameter of resting lymphocytes
  • Necrosis
  • Chromogranin
  • Neuron-specific enolase
  • Synaptophysin
  • Somatostatin
  • CD56
  • Peripheral lesion
  • Expansively growing
  • Irregular margins
  • Mediastinal lymph node enlargement
  • Bronchoscopy (Gold standard for tumor visualization)
  • SSTR (somatostatin receptors ) scintigraphy
  • Biopsy with immunohisto-chemistry
Associated
  • Smoking
  • Humoral hypercalcemia of malignancy
  • SIADH
  • Hypoglycemia
  • Acromegaly
  • Carcinoid syndrome
  • Neurological syndromes
  • Gynecomastia
  • Hyperthyroidism
Small cell lung neuroendocrine carcinomas[88][89][90][91]
  • Asymptomatic
  • Cough
  • Hemoptysis
  • Recurrent infections
  • Seizures
  • ↓ Breath sounds
  • Fever
  • Carcinoid syndrome related (rare)
  • Cushing's syndrome related (rare)
  • ↑ Urinary 5-hydroxyindole-acetic acid (rare)
  • ↑ Serum ACTH (rare)
  • ↑ Chromogranin A
  • Less differentiated
  • Grey-white
  • Invasive
  • Hemorrhage/necrosis
  • Diffuse sheets
  • No prominent neucleoli
  • Cells < size of three small resting lymphocytes
  • The mitotic rate averages over 60 mitoses/2 mm2
  • Extensive necrosis
  • Chromogranin
  • Neuron-specific enolase
  • Synaptophysin
  • Somatostatin
  • CD56
  • Homogeneous or noncontiguous parenchymal mass, or peripheral nodule
  • Adjacent compression
  • Atelectasis
  • Pleural effusion .
  • Intratumoral calcification
  • Lymphadenopathy
  • PET scan
  • Bronchoscopy
  • Scintigraphy
  • Biopsy with immunohisto-chemistry
Associated
  • Smoking
  • Humoral hypercalcemia of malignancy
  • SIADH
  • Hypoglycemia
  • Acromegaly
  • Neurological syndromes
  • Gynecomastia
  • Hyperthyroidism

References

  1. Segura S, Ramos-Rivera G, Suhrland M (2018). "Educational Case: Endocrine Neoplasm: Medullary Thyroid Carcinoma". Acad Pathol. 5: 2374289518775722. doi:10.1177/2374289518775722. PMC 6024338. PMID 29978018.
  2. Roy M, Chen H, Sippel RS (2013). "Current understanding and management of medullary thyroid cancer". Oncologist. 18 (10): 1093–100. doi:10.1634/theoncologist.2013-0053. PMC 3805151. PMID 24037980.
  3. Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K (August 2010). "The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer". Pancreas. 39 (6): 775–83. doi:10.1097/MPA.0b013e3181ebb4f0. PMC 3419007. PMID 20664475.
  4. Martucci VL, Pacak K (2014). "Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment". Curr Probl Cancer. 38 (1): 7–41. doi:10.1016/j.currproblcancer.2014.01.001. PMC 3992879. PMID 24636754.
  5. Kantorovich V, Pacak K (2010). "Pheochromocytoma and paraganglioma". Prog. Brain Res. 182: 343–73. doi:10.1016/S0079-6123(10)82015-1. PMC 4714594. PMID 20541673.
  6. Miller AD, Masek-Hammerman K, Dalecki K, Mansfield KG, Westmoreland SV (November 2009). "Histologic and immunohistochemical characterization of pheochromocytoma in 6 cotton-top tamarins (Saguinus oedipus)". Vet. Pathol. 46 (6): 1221–9. doi:10.1354/vp.09-VP-0022-M-FL. PMID 19605896.
  7. Kantorovich V, Eisenhofer G, Pacak K (December 2008). "Pheochromocytoma: an endocrine stress mimicking disorder". Ann. N. Y. Acad. Sci. 1148: 462–8. doi:10.1196/annals.1410.081. PMC 2693284. PMID 19120142.
  8. Eisenhofer G, Peitzsch M (December 2014). "Laboratory evaluation of pheochromocytoma and paraganglioma". Clin. Chem. 60 (12): 1486–99. doi:10.1373/clinchem.2014.224832. PMID 25332315.
  9. Becker JC, Stang A, DeCaprio JA, Cerroni L, Lebbé C, Veness M, Nghiem P (October 2017). "Merkel cell carcinoma". Nat Rev Dis Primers. 3: 17077. doi:10.1038/nrdp.2017.77. PMC 6054450. PMID 29072302.
  10. Han SY, North JP, Canavan T, Kim N, Yu SS (December 2012). "Merkel cell carcinoma". Hematol. Oncol. Clin. North Am. 26 (6): 1351–74. doi:10.1016/j.hoc.2012.08.007. PMID 23116583.
  11. Amaral T, Leiter U, Garbe C (December 2017). "Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy". Rev Endocr Metab Disord. 18 (4): 517–532. doi:10.1007/s11154-017-9433-0. PMID 28916903.
  12. Wieneke JA, Smith A (December 2008). "Parathyroid adenoma". Head Neck Pathol. 2 (4): 305–8. doi:10.1007/s12105-008-0088-8. PMID 20614300.
  13. Madkhali T, Alhefdhi A, Chen H, Elfenbein D (2016). "Primary hyperparathyroidism". Ulus Cerrahi Derg. 32 (1): 58–66. doi:10.5152/UCD.2015.3032. PMC 4771429. PMID 26985167.
  14. Costa-Guda J, Arnold A (April 2014). "Genetic and epigenetic changes in sporadic endocrine tumors: parathyroid tumors". Mol. Cell. Endocrinol. 386 (1–2): 46–54. doi:10.1016/j.mce.2013.09.005. PMC 3943641. PMID 24035866.
  15. Eisenhofer G, Peitzsch M (December 2014). "Laboratory evaluation of pheochromocytoma and paraganglioma". Clin. Chem. 60 (12): 1486–99. doi:10.1373/clinchem.2014.224832. PMID 25332315.
  16. Baez JC, Jagannathan JP, Krajewski K, O'Regan K, Zukotynski K, Kulke M, Ramaiya NH (May 2012). "Pheochromocytoma and paraganglioma: imaging characteristics". Cancer Imaging. 12: 153–62. doi:10.1102/1470-7330.2012.0016. PMC 3362869. PMID 22571874.
  17. Liu YQ, Yue JQ (2013). "Paraganglioma of the vulva: a case report and review of the literature". Int J Clin Exp Pathol. 6 (10): 2247–50. PMC 3796250. PMID 24133606.
  18. Wang ZH, Wang YT, Cheng F, Hu Y (October 2018). "Pathological features of paraganglioma in the lumbar spinal canal: A case report". Medicine (Baltimore). 97 (41): e12586. doi:10.1097/MD.0000000000012586. PMC 6203573. PMID 30313044.
  19. Amine MM, Mohamed B, Mourad H, Majed H, Slim C, Mehdi B, Hela M, Nouri R, Rim K, Tahya B, Nabil MM (April 2017). "Neuroendocrine Testicular Tumors: A Systematic Review and Meta-Analysis". Curr Urol. 10 (1): 15–25. doi:10.1159/000447146. PMC 5436018. PMID 28559773.
  20. Park SB, Kim JK, Cho KS (March 2006). "Imaging findings of a primary bilateral testicular carcinoid tumor associated with carcinoid syndrome". J Ultrasound Med. 25 (3): 413–6. PMID 16495507.
  21. Eichhorn JH, Young RH (June 2001). "Neuroendocrine tumors of the genital tract". Am. J. Clin. Pathol. 115 Suppl: S94–112. doi:10.1309/64CW-WKGK-49EF-BYD1. PMID 11993694.
  22. Orsi NM, Menon M (August 2016). "Primary ovarian neuroendocrine tumor arising in association with a mature cystic teratoma: A case report". Gynecol Oncol Rep. 17: 83–5. doi:10.1016/j.gore.2016.07.003. PMC 4971231. PMID 27508272.
  23. Kaiho-Sakuma M, Toyoshima M, Watanabe M, Toki A, Kameda S, Minato T, Niikura H, Yaegashi N (February 2018). "Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report". Gynecol Oncol Rep. 23: 20–23. doi:10.1016/j.gore.2018.01.002. PMC 5760241. PMID 29326972.
  24. Eichhorn JH, Young RH (June 2001). "Neuroendocrine tumors of the genital tract". Am. J. Clin. Pathol. 115 Suppl: S94–112. doi:10.1309/64CW-WKGK-49EF-BYD1. PMID 11993694.
  25. Bohnenberger H, Dinter H, König A, Ströbel P (November 2017). "Neuroendocrine tumors of the thymus and mediastinum". J Thorac Dis. 9 (Suppl 15): S1448–S1457. doi:10.21037/jtd.2017.02.02. PMC 5690954. PMID 29201448.
  26. Moran CA, Suster S (July 2000). "Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases". Am. J. Clin. Pathol. 114 (1): 100–10. doi:10.1309/3PDN-PMT5-EQTM-H0CD. PMID 10884805.
  27. Boubacar E, Atsame-Ebang G, Rabiou S, Fatimazahra A, Mazti A, Sidibé IS, Tahiri L, Hammas N, Yassine O, Mohamed S, Laila C, Hinde EF (June 2017). "Thymic large cell neuroendocrine carcinoma - a rare and aggressive tumor: a case report". J Med Case Rep. 11 (1): 155. doi:10.1186/s13256-017-1331-2. PMC 5467048. PMID 28602157.
  28. Domen H, Hida Y, Sato M, Takahashi H, Ishikawa T, Shionoya Y, Hashimoto M, Nishiyama K, Aoki Y, Inoko K, Furukawa S, Ichinokawa K, Yamada H (November 2018). "Resected thymic large cell neuroendocrine carcinoma: report of a case". Surg Case Rep. 4 (1): 133. doi:10.1186/s40792-018-0540-2. PMC 6240022. PMID 30446840.
  29. Abdelaal A, El Ansari W, Al-Bozom I, Khawar M, Shahid F, Aleter A, Abunuwar MR, El-Menyar A (September 2017). "Frequency, characteristics and outcomes of appendicular neuroendocrine tumors: A cross-sectional study from an academic tertiary care hospital". Ann Med Surg (Lond). 21: 20–24. doi:10.1016/j.amsu.2017.07.043. PMID 28761642.
  30. Holt N, Grønbæk H (2013). "Goblet cell carcinoids of the appendix". ScientificWorldJournal. 2013: 543696. doi:10.1155/2013/543696. PMID 23365545.
  31. 31.0 31.1 Gut P, Waligórska-Stachura J, Czarnywojtek A, Sawicka-Gutaj N, Bączyk M, Ziemnicka K, Woliński K, Zybek A, Fischbach J, Ruchała M (October 2017). "Hindgut neuroendocrine neoplasms - characteristics and prognosis". Arch Med Sci. 13 (6): 1427–1432. doi:10.5114/aoms.2017.64979. PMC 5701690. PMID 29181074.
  32. 32.0 32.1 Rindi G, Klöppel G (2004). "Endocrine tumors of the gut and pancreas tumor biology and classification". Neuroendocrinology. 80 Suppl 1: 12–5. doi:10.1159/000080733. PMID 15477709.
  33. Murray SE, Lloyd RV, Sippel RS, Chen H (September 2013). "Clinicopathologic characteristics of colonic carcinoid tumors". J. Surg. Res. 184 (1): 183–8. doi:10.1016/j.jss.2013.05.107. PMC 3759590. PMID 23830363.
  34. Derikx LA, Vierdag WM, Kievit W, Bosch S, Hoentjen F, Nagtegaal ID (August 2016). "Is the prevalence of colonic neuroendocrine tumors increased in patients with inflammatory bowel disease?". Int. J. Cancer. 139 (3): 535–42. doi:10.1002/ijc.30096. PMID 26992110.
  35. Uppin MS, Uppin SG, Sunil CS, Hui M, Paul TR, Bheerappa N (February 2017). "Clinicopathologic study of neuroendocrine tumors of gastroenteropancreatic tract: a single institutional experience". J Gastrointest Oncol. 8 (1): 139–147. doi:10.21037/jgo.2016.12.08. PMC 5334039. PMID 28280618.
  36. Koenig A, Krug S, Mueller D, Barth PJ, Koenig U, Scharf M, Ellenrieder V, Michl P, Moll R, Homayunfar K, Kann PH, Stroebel P, Gress TM, Rinke A (2017). "Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms". PLoS ONE. 12 (12): e0188876. doi:10.1371/journal.pone.0188876. PMC 5726657. PMID 29232390.
  37. Yuan H, Yang Y, Wang W, Cheng Y (September 2018). "A case report of neuroendocrine tumor (G3) at lower rectum with liver metastasis". Medicine (Baltimore). 97 (38): e12423. doi:10.1097/MD.0000000000012423. PMC 6160253. PMID 30235718.
  38. 38.0 38.1 Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, Fazio N, Giammarile F, Hicks RJ, Kjaer A, Krenning E, Kwekkeboom D, Lombard-Bohas C, O'Connor JM, O'Toole D, Rockall A, Wiedenmann B, Valle JW, Vullierme MP (2017). "ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging". Neuroendocrinology. 105 (3): 212–244. doi:10.1159/000471879. PMID 28355596.
  39. 39.0 39.1 Chin JL, O'Toole D (November 2017). "Diagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors". Clin Endosc. 50 (6): 520–529. doi:10.5946/ce.2017.181. PMID 29207862.
  40. Dias AR, Azevedo BC, Alban L, Yagi OK, Ramos M, Jacob CE, Barchi LC, Cecconello I, Ribeiro U, Zilberstein B (2017). "GASTRIC NEUROENDOCRINE TUMOR: REVIEW AND UPDATE". Arq Bras Cir Dig. 30 (2): 150–154. doi:10.1590/0102-6720201700020016. PMID 29257854. Vancouver style error: initials (help)
  41. Pritchard DM (May 2011). "Zollinger-Ellison syndrome: still a diagnostic challenge in the 21st century?". Gastroenterology. 140 (5): 1380–3. doi:10.1053/j.gastro.2011.03.026. PMID 21443889.
  42. Chin JL, O'Toole D (November 2017). "Diagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors". Clin Endosc. 50 (6): 520–529. doi:10.5946/ce.2017.181. PMC 5719910. PMID 29207862.
  43. Dias AR, Azevedo BC, Alban L, Yagi OK, Ramos M, Jacob CE, Barchi LC, Cecconello I, Ribeiro U, Zilberstein B (2017). "GASTRIC NEUROENDOCRINE TUMOR: REVIEW AND UPDATE". Arq Bras Cir Dig. 30 (2): 150–154. doi:10.1590/0102-6720201700020016. PMC 5543797. PMID 29257854. Vancouver style error: initials (help)
  44. Basuroy R, Srirajaskanthan R, Prachalias A, Quaglia A, Ramage JK (May 2014). "Review article: the investigation and management of gastric neuroendocrine tumours". Aliment. Pharmacol. Ther. 39 (10): 1071–84. doi:10.1111/apt.12698. PMID 24628514.
  45. Li TT, Qiu F, Qian ZR, Wan J, Qi XK, Wu BY (January 2014). "Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors". World J. Gastroenterol. 20 (1): 118–25. doi:10.3748/wjg.v20.i1.118. PMID 24415864.
  46. Hosoya Y, Nagai H, Koinuma K, Yasuda Y, Kaneko Y, Saito K (2003). "A case of aggressive neuroendocrine carcinoma of the stomach". Gastric Cancer. 6 (1): 55–9. doi:10.1007/s101200300007. PMID 12673427.
  47. 47.0 47.1 Ro C, Chai W, Yu VE, Yu R (June 2013). "Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment". Chin J Cancer. 32 (6): 312–24. doi:10.5732/cjc.012.10295. PMC 3845620. PMID 23237225.
  48. 48.0 48.1 Zhang WD, Liu DR, Wang P, Zhao JG, Wang ZF, Chen LI (May 2016). "Clinical treatment of gastrinoma: A case report and review of the literature". Oncol Lett. 11 (5): 3433–3437. doi:10.3892/ol.2016.4397. PMC 4840999. PMID 27123130.
  49. 49.0 49.1 Epelboym I, Mazeh H (January 2014). "Zollinger-Ellison syndrome: classical considerations and current controversies". Oncologist. 19 (1): 44–50. doi:10.1634/theoncologist.2013-0369. PMC 3903066. PMID 24319020.
  50. 50.0 50.1 Yang RH, Chu YK (2015). "Zollinger-Ellison syndrome: Revelation of the gastrinoma triangle". Radiol Case Rep. 10 (1): 827. doi:10.2484/rcr.v10i1.827. PMC 4921170. PMID 27408649.
  51. 51.0 51.1 Williamson JM, Thorn CC, Spalding D, Williamson RC (July 2011). "Pancreatic and peripancreatic somatostatinomas". Ann R Coll Surg Engl. 93 (5): 356–60. doi:10.1308/003588411X582681. PMC 3365451. PMID 21943457.
  52. 52.0 52.1 De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, Vinik A, Pacak K, Feliberti E, Perry RR. PMID 25905263. Missing or empty |title= (help)
  53. 53.0 53.1 Dinesh U, Pervatikar SK, Rao R (October 2009). "FNAC diagnosis of pancreatic somatostatinoma". J Cytol. 26 (4): 153–5. doi:10.4103/0970-9371.62187. PMC 3168003. PMID 21938182.
  54. Kim JA, Choi WH, Kim CN, Moon YS, Chang SH, Lee HR (March 2011). "Duodenal somatostatinoma: a case report and review". Korean J. Intern. Med. 26 (1): 103–7. doi:10.3904/kjim.2011.26.1.103. PMC 3056248. PMID 21437171.
  55. Wang B, Zou Y, Zhang H, Xu L, Jiang X, Sun K (2015). "Duodenal gangliocytic paraganglioma: report of two cases and review of literature". Int J Clin Exp Pathol. 8 (9): 9752–9. PMC 4637770. PMID 26617685.
  56. Scheithauer BW, Nora FE, LeChago J, Wick MR, Crawford BG, Weiland LH, Carney JA (November 1986). "Duodenal gangliocytic paraganglioma. Clinicopathologic and immunocytochemical study of 11 cases". Am. J. Clin. Pathol. 86 (5): 559–65. PMID 2877566.
  57. Lei L, Cobb C, Perez MN (April 2016). "Functioning gangliocytic paraganglioma of the ampulla: clinicopathological correlations and cytologic features". J Gastrointest Oncol. 7 (Suppl 1): S107–13. doi:10.3978/j.issn.2078-6891.2015.028. PMC 4783616. PMID 27034808.
  58. Sánchez-Pérez MA, Luque-de León E, Muñoz-Juárez M, Moreno-Paquentin E, Genovés-Gómez H, Torreblanca-Marín MA (April 2009). "Duodenal gangliocytic paraganglioma". Can J Surg. 52 (2): E27–8. PMC 2673151. PMID 19399194.
  59. Vanoli A, La Rosa S, Klersy C, Grillo F, Albarello L, Inzani F, Maragliano R, Manca R, Luinetti O, Milione M, Doglioni C, Rindi G, Capella C, Solcia E (2017). "Four Neuroendocrine Tumor Types and Neuroendocrine Carcinoma of the Duodenum: Analysis of 203 Cases". Neuroendocrinology. 104 (2): 112–125. doi:10.1159/000444803. PMID 26910321.
  60. Vanoli A, La Rosa S, Klersy C, Grillo F, Albarello L, Inzani F, Maragliano R, Manca R, Luinetti O, Milione M, Doglioni C, Rindi G, Capella C, Solcia E (2017). "Four Neuroendocrine Tumor Types and Neuroendocrine Carcinoma of the Duodenum: Analysis of 203 Cases". Neuroendocrinology. 104 (2): 112–125. doi:10.1159/000444803. PMID 26910321.
  61. Ilett EE, Langer SW, Olsen IH, Federspiel B, Kjær A, Knigge U (April 2015). "Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review". Diagnostics (Basel). 5 (2): 119–76. doi:10.3390/diagnostics5020119. PMC 4665594. PMID 26854147.
  62. Tsai SD, Kawamoto S, Wolfgang CL, Hruban RH, Fishman EK (June 2015). "Duodenal neuroendocrine tumors: retrospective evaluation of CT imaging features and pattern of metastatic disease on dual-phase MDCT with pathologic correlation". Abdom Imaging. 40 (5): 1121–30. doi:10.1007/s00261-014-0322-7. PMC 4450119. PMID 25504375.
  63. Hirabayashi K, Zamboni G, Nishi T, Tanaka A, Kajiwara H, Nakamura N (2013). "Histopathology of gastrointestinal neuroendocrine neoplasms". Front Oncol. 3: 2. doi:10.3389/fonc.2013.00002. PMC 3551285. PMID 23346552.
  64. Mathur A, Gorden P, Libutti SK (October 2009). "Insulinoma". Surg. Clin. North Am. 89 (5): 1105–21. doi:10.1016/j.suc.2009.06.009. PMC 3470467. PMID 19836487.
  65. Shin JJ, Gorden P, Libutti SK (February 2010). "Insulinoma: pathophysiology, localization and management". Future Oncol. 6 (2): 229–37. doi:10.2217/fon.09.165. PMID 20146582.
  66. Dromain C, Déandréis D, Scoazec JY, Goere D, Ducreux M, Baudin E, Tselikas L (December 2016). "Imaging of neuroendocrine tumors of the pancreas". Diagn Interv Imaging. 97 (12): 1241–1257. doi:10.1016/j.diii.2016.07.012. PMID 27876341.
  67. Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, Kobayashi M, Hanazaki K (February 2013). "Diagnosis and management of insulinoma". World J. Gastroenterol. 19 (6): 829–37. doi:10.3748/wjg.v19.i6.829. PMC 3574879. PMID 23430217.
  68. Ro C, Chai W, Yu VE, Yu R (June 2013). "Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment". Chin J Cancer. 32 (6): 312–24. doi:10.5732/cjc.012.10295. PMC 3845620. PMID 23237225.
  69. Song X, Zheng S, Yang G, Xiong G, Cao Z, Feng M, Zhang T, Zhao Y (March 2018). "Glucagonoma and the glucagonoma syndrome". Oncol Lett. 15 (3): 2749–2755. doi:10.3892/ol.2017.7703. PMC 5778850. PMID 29435000.
  70. Sandhu S, Jialal I. PMID 30137784. Missing or empty |title= (help)
  71. Wei J, Song X, Liu X, Ji Z, Ranasinha N, Wu J, Miao Y (2018). "Glucagonoma and Glucagonoma Syndrome: One Center's Experience of Six Cases". J Pancreat Cancer. 4 (1): 11–16. doi:10.1089/pancan.2018.0003. PMC 5999015. PMID 30631852.
  72. De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, Vinik A. PMID 25905195. Missing or empty |title= (help)
  73. Lubinski SM, Hendrix T (August 2004). "Images in clinical medicine. VIPoma". N. Engl. J. Med. 351 (8): 808. doi:10.1056/NEJMicm960440. PMID 15317894.
  74. Sandhu S, Jialal I. PMID 29939520. Missing or empty |title= (help)
  75. Elshafie O, Grant C, Al-Hamdani A, Jain R, Woodhouse N (February 2011). "VIPoma Crisis: Immediate and life saving reduction of massive stool volumes on starting treatment with octreotide". Sultan Qaboos Univ Med J. 11 (1): 104–7. PMID 21509215.
  76. Sun J (February 2017). "Pancreatic neuroendocrine tumors". Intractable Rare Dis Res. 6 (1): 21–28. doi:10.5582/irdr.2017.01007. PMID 28357177.
  77. Maragliano R, Vanoli A, Albarello L, Milione M, Basturk O, Klimstra DS, Wachtel A, Uccella S, Vicari E, Milesi M, Davì MV, Scarpa A, Sessa F, Capella C, La Rosa S (March 2015). "ACTH-secreting pancreatic neoplasms associated with Cushing syndrome: clinicopathologic study of 11 cases and review of the literature". Am. J. Surg. Pathol. 39 (3): 374–82. doi:10.1097/PAS.0000000000000340. PMID 25353285.
  78. Ito T, Igarashi H, Jensen RT (December 2012). "Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances". Best Pract Res Clin Gastroenterol. 26 (6): 737–53. doi:10.1016/j.bpg.2012.12.003. PMC 3627221. PMID 23582916.
  79. Byun J, Kim SH, Jeong HS, Rhee Y, Lee WJ, Kang CM (February 2017). "ACTH-producing neuroendocrine tumor of the pancreas: a case report and literature review". Ann Hepatobiliary Pancreat Surg. 21 (1): 61–65. doi:10.14701/ahbps.2017.21.1.61. PMC 5353908. PMID 28317048.
  80. 80.0 80.1 Fisseler-Eckhoff A, Demes M (July 2012). "Neuroendocrine tumors of the lung". Cancers (Basel). 4 (3): 777–98. doi:10.3390/cancers4030777. PMC 3712715. PMID 24213466.
  81. 81.0 81.1 Yang Z, Wang Z, Duan Y, Xu S (November 2016). "Clinicopathological characteristics and prognosis of resected cases of carcinoid tumors of the lung". Thorac Cancer. 7 (6): 633–638. doi:10.1111/1759-7714.12377. PMID 27755793.
  82. 82.0 82.1 Herde RF, Kokeny KE, Reddy CB, Akerley WL, Hu N, Boltax JP, Hitchcock YJ (January 2018). "Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience". Am. J. Clin. Oncol. 41 (1): 24–29. doi:10.1097/COC.0000000000000221. PMID 26270444.
  83. 83.0 83.1 Papaxoinis G, Lamarca A, Quinn AM, Mansoor W, Nonaka D (May 2018). "Clinical and Pathologic Characteristics of Pulmonary Carcinoid Tumors in Central and Peripheral Locations". Endocr. Pathol. doi:10.1007/s12022-018-9530-y. PMC 6097045. PMID 29770932.
  84. Hiroshima K, Mino-Kenudson M (October 2017). "Update on large cell neuroendocrine carcinoma". Transl Lung Cancer Res. 6 (5): 530–539. doi:10.21037/tlcr.2017.06.12. PMC 5653527. PMID 29114469.
  85. Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F (August 2015). "Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy". J Thorac Oncol. 10 (8): 1133–41. doi:10.1097/JTO.0000000000000589. PMC 4503246. PMID 26039012.
  86. Fisseler-Eckhoff A, Demes M (July 2012). "Neuroendocrine tumors of the lung". Cancers (Basel). 4 (3): 777–98. doi:10.3390/cancers4030777. PMC 3712715. PMID 24213466.
  87. Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, Dobashi H, Matsunaga T (August 2014). "Paraneoplastic syndromes associated with lung cancer". World J Clin Oncol. 5 (3): 197–223. doi:10.5306/wjco.v5.i3.197. PMC 4127595. PMID 25114839.
  88. Hiroshima K, Mino-Kenudson M (October 2017). "Update on large cell neuroendocrine carcinoma". Transl Lung Cancer Res. 6 (5): 530–539. doi:10.21037/tlcr.2017.06.12. PMC 5653527. PMID 29114469.
  89. Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F (August 2015). "Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy". J Thorac Oncol. 10 (8): 1133–41. doi:10.1097/JTO.0000000000000589. PMC 4503246. PMID 26039012.
  90. Fisseler-Eckhoff A, Demes M (July 2012). "Neuroendocrine tumors of the lung". Cancers (Basel). 4 (3): 777–98. doi:10.3390/cancers4030777. PMC 3712715. PMID 24213466.
  91. Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, Dobashi H, Matsunaga T (August 2014). "Paraneoplastic syndromes associated with lung cancer". World J Clin Oncol. 5 (3): 197–223. doi:10.5306/wjco.v5.i3.197. PMC 4127595. PMID 25114839.